EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, Biological Evaluation, and In Silico Studies of New Nitazoxanide Derivatives: Toward Broad‐Spectrum Antimicrobial Agents

Mahmoud Saleh iD, Momen M Thabet, Jyothi Kumari, Yaser A Mostafa, Dharmarajan Sriram, Keisuke Suganuma, Mahmoud Kandeel iD, Hajjaj H M Abdu-Allah iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Mahmoud Saleh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt. Hauptthemen laut MEDLINE: Drug Design, Anti-Bacterial Agents, Thiazoles. Die Arbeit nennt 78 Literaturangaben. Gefördert von: The authors appreciate the support provided by the Faculty of Pharmacy, Assiut University, Assiut, Egypt. Also, this work was supported by the Deanship of Scie….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nitazoxanide (NTZ), an FDA‐approved drug, served as the framework for synthesizing 22 new broad‐spectrum antimicrobial agents from 4‐aminosalicylic acid via protection–deprotection, Staudinger reduction, Clauson–Kaas pyrrole synthesis, and nucleophilic substitution. These compounds were evaluated for antibacterial, antimycobacterial, and antitrypanosomal activities. Several compounds, particularly 10 , 11 , 13 , and 22 , surpassed the antibacterial activity of NTZ and its active metabolite tizoxanide (TIZ) against all tested pathogens, with MICs ranging from 1.025 to 9.81 μM. Compounds 10 and 13 were twice as potent as ciprofloxacin against Klebsiella pneumoniae , while 11 and 17 were equipotent against Pseudomonas aeruginosa (MIC 5.34 μM). Compounds 11 and 14 matched ciprofloxacin against Staphylococcus aureus (MIC 3.20 and 2.98 µM), whereas 13 and 21 were 1.5‐ and 2.5‐fold more potent against Enterococcus faecalis , respectively. Compound 10 outperformed ciprofloxacin against Helicobacter pylori (MIC 1.025 μM). Compounds 6 (MIC 9.46 μM) and 7 (MIC 16.78 μM) outperformed NTZ against Mycobacterium t uberculosis , and compound 3 emerged as a promising antitrypanosomal agent (MICs 2.59–4.73 μg/mL) against six Trypanosoma species. Cytotoxicity and pharmacokinetic studies confirmed the compounds’ favorable drug‐like properties and high selectivity. Docking results showed strong binding to key targets like pyruvate ferredoxin oxidoreductase (PFOR), glucosamine‐6‐phosphate synthase (G6PS), dihydrofolate reductase (DHFR), and ornithine decarboxylase (ODC). Overall, several NTZ derivatives, particularly compounds 3 , 6 , 10 , 11 , 13 , and 22 , showed potent broad‐spectrum antimicrobial activity and offer convenient leads for further optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignAnti-Bacterial AgentsThiazolesMicrobial Sensitivity TestsStructure-Activity RelationshipMolecular StructureNitro CompoundsAnimalsHumansDose-Response Relationship, DrugMolecular Docking SimulationComputer SimulationGram-Positive Bacteria

Stichwörter der Autor:innen

Clauson–Kaas reactionESKAPEStaudinger reductionantimicrobialcytotoxicitydockingnitazoxanidetrypanosomes

Substanzen

nitazoxanideAnti-Bacterial AgentsThiazolesNitro Compounds

Autor:innen und Institutionen

  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
  • Microbiology and Immunology Department, Faculty of Pharmacy, South Valley University, Qena, Egypt.
  • Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, India.
  • National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Japan.
  • Research Center for Global Agromedicine, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Japan.
  • Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia.

ORCID-Profile: Mahmoud Saleh, Mahmoud Kandeel, Hajjaj H M Abdu-Allah

Förderung

  • The authors appreciate the support provided by the Faculty of Pharmacy, Assiut University, Assiut, Egypt. Also, this work was supported by the Deanship of Scie…

Zitieren

APA

Saleh, M., Thabet, M. M., Kumari, J., Mostafa, Y. A., Sriram, D., Suganuma, K., Kandeel, M., & Abdu-Allah, H. H. M. (2025). Design, Synthesis, Biological Evaluation, and In Silico Studies of New Nitazoxanide Derivatives: Toward Broad‐Spectrum Antimicrobial Agents. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70091

Vancouver

Saleh M, Thabet MM, Kumari J, Mostafa YA, Sriram D, Suganuma K, et al. Design, Synthesis, Biological Evaluation, and In Silico Studies of New Nitazoxanide Derivatives: Toward Broad‐Spectrum Antimicrobial Agents. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70091

BibTeX
@article{Saleh2025,
  author = {Saleh, Mahmoud and Thabet, Momen M and Kumari, Jyothi and Mostafa, Yaser A and Sriram, Dharmarajan and Suganuma, Keisuke and Kandeel, Mahmoud and Abdu-Allah, Hajjaj H M},
  title = {Design, Synthesis, Biological Evaluation, and In Silico Studies of New Nitazoxanide Derivatives: Toward Broad‐Spectrum Antimicrobial Agents},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70091}
}
Kostenlos starten →